Skip to main content
CTEV
NYSE Trade & Services

Claritev Tops Q2 Estimates and Lifts Full-Year Outlook on Surging Bookings

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$26.84
Mkt Cap
$457.563M
52W Low
$11.5
52W High
$74.07
52W Position info
133% above low
Off High info
64% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CTEV has more than doubled off its 52-week low of $11.5.

Summary

Claritev posted Q2 2026 revenue of $257.5M (up 6.6% YoY) and adjusted EBITDA of $155.8M, beating expectations. The company raised full-year guidance and highlighted $70M+ in H1 bookings, signaling accelerating growth.


Key Events · Earnings and Guidance · CTEV

  • Q2 Revenue and EBITDA Beat

    Revenue of $257.5M grew 6.6% YoY, beating consensus by 5.2%. Adjusted EBITDA of $155.8M (60.5% margin) beat by 3.5%, though margin compressed from 63.8% a year ago.

  • Full-Year Guidance Raised

    Revenue guidance lifted to $1B-$1.02B (from $985M-$1B), Adjusted EBITDA to $610M-$620M (from $605M-$615M), and Free Cash Flow to $5M-$15M (from $0M-$10M).

  • Bookings Momentum Accelerating

    Over $70M in bookings in H1 2026, on pace for $100M full-year target — a 50% increase over 2025. Strength was broad-based across solutions and verticals, with notable TPA wins.

  • Cash Flow and Balance Sheet

    Operating cash flow surged to $92.7M in Q2 (vs. $61.2M a year ago). Unrestricted cash remains low at $14.4M, with $70M drawn on the revolver, but free cash flow turned positive at $54.6M for the quarter.


Analysis · CTEV · Trade & Services

A strong Q2 beat across the board underscores the turnaround: revenue of $257.5M exceeded consensus by 5.2%, and adjusted EBITDA of $155.8M came in 3.5% ahead of expectations, prompting a raise in full-year revenue and EBITDA guidance. Bookings momentum is accelerating—over $70M in the first half puts the company on track for $100M in 2026, a 50% jump over 2025. While the balance sheet remains tight with only $14.4M in unrestricted cash, operating cash flow improved sharply to $92.7M in the quarter. This print reinforces the turnaround narrative and validates the Vision 2030 transformation program, coming just two months after the DOJ closed its antitrust probe without action.

At the time of this filing, CTEV was trading at $26.84 on NYSE in the Trade & Services sector, with a market capitalization of approximately $457.6M. The 52-week trading range was $11.50 to $74.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CTEV - Latest Insights

CTEV
Aug 07, 2026, 5:13 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $26.84
Real-time Price: $26.84 info
Change: $0 (0%) info
Market Cap: $457.563M info
CTEV
Jul 30, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $23.40
Real-time Price: $26.84 info
Change: +$3.44 (+15%) info
Market Cap: $457.563M info
CTEV
Jun 22, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $28.77
Real-time Price: $26.84 info
Change: -$1.93 (-7%) info
Market Cap: $457.563M info
CTEV
Jun 22, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $28.44
Real-time Price: $26.84 info
Change: -$1.60 (-6%) info
Market Cap: $457.563M info
CTEV
May 18, 2026, 12:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.71
Real-time Price: $26.84 info
Change: +$15.13 (+129%) info
Market Cap: $457.563M info